Compare AbbVie Inc (ABBV) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.59. The key difference: AbbVie Inc pays a 2.72% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals.
| ABBV | SPHD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $52.63 |
52-Week Low | $184.85 | $46.96 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
SPHD trades at $51.64, down 0.92% today, with a bullish technical outlook supported by moving averages and strong trend indicators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% SEC yield with monthly distributions. Recent news highlights its role in retirement income strategies, though long-term performance has trailed the broader market.
The outlook for SPHD is cautiously positive for income-focused investors seeking stability, with technical strength and defensive positioning. Key risks include underperformance during bull markets and sensitivity to interest rate changes. Analyst sentiment is mixed, balancing yield appeal against growth limitations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
